SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Alembic Pharma receives EIR from USFDA for Panelav facility

15 Jun 2018 Evaluate

Alembic Pharmaceuticals has received Establishment Inspection Report (EIR) from United States Food and Drug Administration (USFDA) for the inspection carried out by them at Formulation Facility at Panelav during the period from 12th March, 2018 to 20th March, 2018.

Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, has been at the forefront of Healthcare since 1907.

Alembic Pharma Share Price

768.70 3.80 (0.50%)
05-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1820.75
Dr. Reddys Lab 1270.95
Cipla 1333.55
Zydus Lifesciences 911.85
Lupin 2343.40
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×